Secukinumab (Cosentyx®) for moderate to severe plaque psoriasis

Assessment Status Assessment Process Complete
Drug Secukinumab
Brand Cosentyx®
Indication For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Assessment Process
Rapid review commissioned 19/12/2014
Rapid review completed 05/02/2015
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 02/04/2015
NCPE assessment completed 16/09/2015
NCPE assessment outcome Reimbursement Not Recommended at the Submitted Price.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations December 2015.